Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | BCR | P11274 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13020192 | 0.84 | SIGMAR1 (0.58) | MAPK14SIGMAR1ABL1BCRALDH1A1 | |
| SCHEMBL3784641 | 0.79 | MAPK14 (0.55) | MAPK14SIGMAR1ABL1BCRALDH1A1 | |
| SCHEMBL13020233 | 0.74 | KDM4E (0.47) | ALDH1A1 | |
| SCHEMBL19700806 | 0.73 | POLB (0.55) | MAPK14ABL1BCRALDH1A1CYP1A2 | |
| SCHEMBL13840202 | 0.73 | KDM4E (0.46) | ALDH1A1 | |
| SCHEMBL22521559 | 0.69 | CYP1A2 (0.47) | MAPK14ABL1BCRALDH1A1TDP1 | |
| SCHEMBL13020021 | 0.69 | HTT (0.78) | MAPK14ABL1ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL3778676 | 0.68 | CCR4 (0.49) | MAPK14ABL1BCRALDH1A1 | |
| SCHEMBL22521558 | 0.67 | ABL1 (0.45) | MAPK14ABL1BCRALDH1A1CYP1A2 | |
| SCHEMBL4569746 | 0.67 | ABL1 (0.45) | MAPK14ABL1BCRALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | MAPK14 1189/4885SIGMAR1 1727/4885ABL1 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.